Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ABL Bio Inc. logo — A global leader in bispecific antibody therapeutics for immu...

ABL Bio Inc.

A global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases.

Founded 2016 Korea South Korea South 64 employees IPO Total: $49.12B Biotechnology, Health Care

General Information

Company Name ABL Bio Inc.
Founded Year 2016
Location Korea South Korea South
Founders / Decision Makers
Team member
Employees 64
Industries Biotechnology, Health Care
Funding Stage IPO
Business Model B2B, Platform
Revenue Model Licensing, Performance Based
Offices as of Nov 2026
‏Seoul‏، ‏Gangnam-gu‏ ‏06153‏، ‏KR‏, ‏Seoul‏، ‏Gangnam-gu‏ ‏06153‏، ‏KR‏
Social

BounceWatch is an independent company data service, not affiliated with ABL Bio Inc.. To contact ABL Bio Inc., visit ablbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ABL Bio Inc. compare?

A PDF of ABL Bio Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ABL Bio Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 19, 2026

Clinical data on givastomig and ragistomig will be presented as posters at the ESMO Congress.

ABL Bio Inc. a competitor of yours? Have our desk watch it

About ABL Bio Inc.

ABL Bio Inc., founded in 2016 and headquartered in Korea South, stands as a prominent figure in the biotechnology space. Known for being a global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases, the company has carved out a niche in delivering innovative health care solutions.

Employing its proprietary platforms like ‘Grabody-T’, ‘Grabody-I’, and ‘Grabody-B’, ABL Bio has established a diverse pipeline of drug candidates targeting oncology and neurodegenerative disorders. Notably, their Grabody-T platform has shown potent efficacy in cancer treatments, whereas Grabody-B aims to revolutionize CNS drug delivery by enhancing blood-brain barrier penetration.

The company's strategic prowess is also reflected through its collaborations, highlighted by a recent $55.00M post-IPO equity investment led by Eli Lilly on 01 December 2025. This investment underscores their growth potential and commitment to pioneering medical advancements.

Business keywords: Bispecific Antibody Therapeutics, Immuno-Oncology, Neurodegenerative Diseases, Grabody-T, Grabody-I, Grabody-B, 4-1BB Engagement, Blood-Brain Barrier Penetration, Clinical Stage Drug Candidates, Pre-Clinical Stage Drug Candidates, Antibody Drug Conjugate, CNS Targets, Strategic Partnerships, Next-Generation Antibody

Services & Products

Development of innovative therapeutic drugs
Research and development of cancer and neurodegenerative disease treatments
Creating and managing biopharmaceutical platforms
Clinical trials and regulatory approval processes

Target Customers

Healthcare providers Patients with cancer and neurodegenerative diseases Pharmaceutical companies Medical researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity $55.00M 1
Eli Lilly
Eli Lilly
01 Dec 2025
IPO Undisclosed -
01 Dec 2018
Series C $65.00M 4
DS Asset Management QUAD Investment Management Hana Financial Investment
DS Asset Management, QUAD Investment Management +2
01 Jun 2018
Series B KRW20.00B 2
Korea Investment Partners DSC Investment
Korea Investment Partners, DSC Investment
01 Mar 2017
Series B KRW20.00B 1
DSC Investment
DSC Investment
01 Jan 2017
Series A KRW9.00B 1
DSC Investment
DSC Investment
01 Jul 2016

ABL Bio Inc. Alternatives & Competitors

View All Alternatives
ABL Bio Inc. vs
Oxford BioTherapeutics
Oxford BioTherapeutics United Kingdom

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms

66 employees
Biotechnology, Health Care
Compare ABL Bio Inc. vs Oxford BioTherapeutics
ABL Bio Inc. vs
Novelty Nobility Inc.
Novelty Nobility Inc. Korea South

Novel Science, Noble Management

Series B
10 employees
Biotechnology, Health Care
Compare ABL Bio Inc. vs Novelty Nobility Inc.
ABL Bio Inc. vs
Alector
Alector United States

We are on a mission to make brain disorders history.

IPO
141 employees
Biotechnology, Health Care
Also compare with: ABL Bio Inc. vs Lys Therapeutics Lys Therapeutics View all alternatives

FAQ About ABL Bio Inc.

A global leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases.
ABL Bio Inc. was founded in 2016.
ABL Bio Inc. is headquartered in Korea South. As of Nov 2026, it also has offices in ‏Seoul‏، ‏Gangnam-gu‏ ‏06153‏، ‏KR‏, ‏Seoul‏، ‏Gangnam-gu‏ ‏06153‏، ‏KR‏.
ABL Bio Inc. operates in Biotechnology and Health Care. Its work centres on Bispecific Antibody Therapeutics, Immuno-Oncology, Neurodegenerative Diseases and Grabody-T. Its customers include Healthcare providers, Patients with cancer and neurodegenerative diseases and Pharmaceutical companies.
ABL Bio Inc. has a B2B and Platform business model. Its revenue comes from Licensing and Performance Based.
ABL Bio Inc. has approximately 64 employees.
ABL Bio Inc. has completed 6 funding rounds, raising a total of $49.12B. The latest funding stage is IPO.
ABL Bio Inc. offers: Development of innovative therapeutic drugs, Research and development of cancer and neurodegenerative disease treatments, Creating and managing biopharmaceutical platforms, Clinical trials and regulatory approval processes.
Top alternatives and competitors to ABL Bio Inc. include Oxford BioTherapeutics, Novelty Nobility Inc., Alector, Immunitas Therapeutics, Apexigen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ABL Bio Inc. and Oxford BioTherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ABL Bio Inc., https://bouncewatch.com/company/abl-bio-inc, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout